Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeKETOTOFEN
Posted by drsaluja on 01 Jan 2014 at 11:42 GMT
If this work was to be translated to a clinical trial,would ketotifen be speculated to have the same role?
RE: KETOTOFEN
niallhyland replied to drsaluja on 03 Jan 2014 at 09:55 GMT
The selectivity of mast cell stabilisers for particular mast cell populations (CTMC, MMC or both) appears to differ across species. However, pre-clinically ketotifen is thought to display selectivity for CTMC. Clinically, ketotifen has been demonstrated to decrease visceral hypersensitivity in patients with irritable bowel syndrome (Gut. 2010 Sep;59(9):1213-21. doi: 10.1136/gut.2010.213108). However, as in our pre-clinical study, whether this occurs solely due to mast cell stabilisation warrants further investigation.